- Rating
- 1
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 1
Read review
Paper summary
The paper studies structural modality missingness. Here the source domain has an auxiliary modality that the target domain lacks. The raw features of the two domains may be disjoint, and a noisy external knowledge graph is the only link between them. GraphBridge anchors the variables of each domain to node families of the graph and keeps the relations that are supported by the literature and useful in both domains. From this transferable graph it builds a low-dimensional spectral bridge. It then learns on the source a transport map from the bridge to a latent factor of the missing modality and applies it to the target. The paper gives finite-sample results for a simplified version and evaluates the method on synthetic data and the PLATO drug-response benchmark with BioKG.
Critical strengths
- The paper formulates a practical setting that, existing missing-modality and domain-adaptation methods typically do not cover. The method gives each difficulty its own component. An abstention option handles variables with weak or ambiguous evidence, and a validation safeguard chooses between the transfer predictor and a target-only baseline to avoid negative transfer.
Critical weaknesses
-
Some GDSC results are hard to reconcile with the method as defined. By the paper's equations, the target bridge is a linear map of fewer than a hundred target genes. With LightGBM, however, the bridge arm beats the oracle arm, which uses the true source-only factor, on most pairs (Tables 7 and 8). An explanation would help.
-
The two main steps, learning the transferable graph and transporting the source-only modality, are not shown to help. On GDSC with LightGBM, the bridge arm beats the transfer arm on every pair. App. H.6 also shows that in the analyzed model, adding the transported factor does not change the least-squares fit. Results for the naive-KG variant listed in App. E.7 would show what the learned graph adds.
Questions for authors
-
What is a row in the PLATO cohorts, and could the masked drug columns reach the target bridge through anchoring, aggregation or standardization? Do the results hold when those columns are removed before running GraphBridge?
-
What do the naive-KG variant, a random graph and the validation-selected predictor achieve on the PLATO pairs?
-
How are the "C. Br." and oracle in Tables 7 to 10 built? With LightGBM, "C. Br." is the best non-oracle arm on every GDSC pair. The LightGBM oracle equals the raw arm on the four pairs with CH as the target.
-
On the GDSC pairs in Table 2, KGAT's raw reaches 0.87 to 0.90, close to the Ridge and PLATO oracles. What inputs do the KGAT and PLATO receive?
-
How were the default hyperparameters in App. L chosen? For example, were they tuned on the evaluated pairs?